SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is experiencing a sharp rebound, driven by renewed analyst confidence in robust AI server CPU demand and strategic leadership additions sparking major partnership speculation. While some in the community eye this as a significant buying opportunity, others remain wary of a 'dead cat bounce' following its post-earnings volatility.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc is trending after its CFO and General Counsel abruptly departed amidst an ongoing SEC accounting probe, invalidated financial disclosures, and significantly lowered guidance, triggering a massive stock sell-off. While many in the community express serious concerns about the company's financial integrity and long-term outlook, others view the steep decline as an overreaction and a potential opportunity for a bounce.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health (OSCR) is trending sharply higher after the House passed a bill to extend ACA subsidies, fueling investor optimism for significant upside and a potential short squeeze, though community debate persists on the bill's Senate fate and the company's path to profitability ahead of its upcoming earnings.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio Inc. is trending after the FDA issued a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, raising concerns about trial design and following a clinical hold on a related program due to a patient tumor; community discussion is split between fears of significant setbacks and a belief that other key pipeline assets, like the AbbVie partnership, still offer substantial value.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify (SPOT) is seeing heated debate leading into its Q4 earnings report, as bullish analysts and the rollout of new AI-powered features and price hikes contend with investor concerns over its valuation and a recent music catalog leak.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is trending after its NASDAQ debut was swiftly followed by a significant equity raise and reverse stock split, sparking a fierce debate among investors over immediate dilution versus the long-term funding for its potentially "revolutionary" muscle regeneration drug for Duchenne Muscular Dystrophy.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following news of Apollo Global Management's $3.4 billion loan for xAI to acquire its chips, reinforcing the massive, multi-year AI infrastructure buildout that has the community highly anticipating upcoming earnings amidst strong bullish sentiment.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following mixed earnings results that highlighted profitability alongside a revenue miss and cautious forward guidance, prompting community discussion around the stock's perceived deep undervaluation. Investors are actively debating whether the significant share price drop is an overreaction to management's prudent risk management strategy within a challenging fintech environment, with many seeing it as a buying opportunity for the AI-driven lending platform.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending ahead of its highly anticipated Q4 earnings report, with community sentiment sharply divided between expectations of a significant rally driven by potential profitability and AI lending growth, and fears of further declines amidst recent fintech sector weakness. Many current holders express frustration over recent price action while looking for a short squeeze, contrasted by bears anticipating a post-earnings dip.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

The community is actively discussing Rocket Companies following its CEO's optimistic remarks about achieving multi-year highs in mortgage loan volume and gain-on-sale performance, leading to expectations of a significant re-rating as its integrated platform benefits from housing market normalization and industry consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors&#8217; attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity&#8217;s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...

Propanc Biopharma tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume, aligning with the volatile trend the stock has been witnessing since the cancer drug developer completed its move from the OTC Pink market to the Nasdaq Capital Market and announced a $4 million share sale.Propanc tumbled nearly 20% in premarket trading Tuesday, after more than doubling on Monday in its best session in four months with a 103.8% gain to $5.85.The company said on Aug. 14 it had secured approval to uplist, with trading on Nasdaq starting Aug. 15 under the same “PPCB” ticker. Its shares were last quoted on the OTC Pink at the close of business Aug. 14.On Thursday, Propanc priced the one million shares at $4 each, targeting $4 million in gross proceeds before costs, and gave underwriters a 45-day option to buy another 150,000 shares.&nbsp;The deal is expected to close on Aug. 18, led by D. Boral Capital and Craft Capital Management.&nbsp;A registration statement for the offering was declared effective by the SEC on Aug. 13.The Melbourne-based biotech said it plans to use the cash for working capital and general expenses.&nbsp;Propanc is developing a proenzyme therapy designed to block the spread and recurrence of solid tumors such as pancreatic, ovarian and colorectal cancers by attacking cancer stem cells.On Stocktwits, retail sentiment for Propanc was ‘extremely bullish’ amid ‘extremely high’ message volume, making it one of the most trending equities on the platform.&nbsp;One user noted that Propanc was looking strong with volume picking up and the chart setting up for what could be the start of a big run.&nbsp;<stembedurl>https://stocktwits.com/Elena11898/message/625706251</stembedurl>Another user remarked that it was lucky no funds chased the stock that day, adding that a drop under $2 might come tomorrow.<stembedurl>https://stocktwits.com/letuan7/message/625718778</stembedurl><a href="https://stocktwits.com/symbol/PPCB">Propanc’s stock</a> has declined 51.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Propanc Biopharma (PPCB) tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume. (Photo credit: Getty Images)

Why Propanc stock Is Tumbling In Premarket Today

The biotech firm announced a $4 million share sale alongside its Nasdaq uplisting, sending trading volumes surging to record levels. 

Equity

This account has been verified as an official PPCB representative.

Verified Account

IR Propanc Bio

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

Propanc Biopharma Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$0.195
Prev Close	$0.1898
Open	$0.1841
Dividend Yield	0.00%
50-Day Moving Average	$0.5481
Beta	0.00
Avg. Volume	646,918.75
PE Ratio	0.00

52-Week High	$11.00
52-Week Low	$0.1555
Market Capitalization	$2.54M
EPS (Annual)	-$14.85
Price to Book	0.17
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PPCB
Propanc Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PPCB News

PPCBPropanc Biopharma Inc